Who Should NOT Take GLP-1 Medications? Full Contraindications List
Medically Reviewed by
Board Certified Endocrinologist
Published
Mar 15, 2026
Last Reviewed
Mar 18, 2026
Sources
5 peer-reviewed
Standard
YMYL / E-E-A-T
Who Should NOT Take GLP-1 Drugs?
GLP-1 receptor agonists — including Ozempic, Wegovy, Mounjaro, and Zepbound — are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). These are FDA black-box warnings that apply to every GLP-1 drug currently on the market. Additional contraindications include prior severe hypersensitivity reactions to a GLP-1 compound, active pancreatitis, and pregnancy. Understanding who cannot safely use these medications is as important as understanding who benefits from them.
FDA Black-Box Warnings: Thyroid Cancer Risk
All GLP-1 receptor agonists carry a boxed warning about thyroid C-cell tumors, the most serious category of FDA warning. In animal studies (rodents), semaglutide and liraglutide produced thyroid C-cell tumors at clinically relevant exposures. While causation in humans has not been established, the FDA requires this warning because the risk cannot be excluded. Patients who have ever been diagnosed with MTC, or who have first-degree relatives with MTC or MEN 2 syndrome, must not use any GLP-1 medication. Before prescribing, your physician should take a thorough family history focused on endocrine tumors.
Pancreatitis: Active and History-Related Risk
Acute pancreatitis has been reported with GLP-1 therapy. Patients with active pancreatitis should never start these medications. Those with a prior history of pancreatitis require careful evaluation — while prior pancreatitis is not an absolute contraindication in all guidelines, most prescribing physicians treat it as one due to the lack of data on re-challenge safety. Patients should be counseled to report persistent severe abdominal pain immediately, as this may signal acute pancreatitis even during established therapy.
Pregnancy, Breastfeeding, and Women of Childbearing Age
GLP-1 medications are contraindicated in pregnancy. Animal reproductive studies have shown fetal harm at doses used in humans. Women of childbearing potential should use effective contraception during therapy and for at least two months after stopping semaglutide (the half-life is approximately one week, but a conservative washout is advised). GLP-1 drugs have not been studied in breastfeeding and should be avoided. Interestingly, GLP-1 therapy has been used in women with PCOS to restore ovulation — meaning improved fertility is possible, and unintended pregnancy is a real risk if contraception is not used.
Kidney Disease and Liver Conditions
GLP-1 drugs are not renally excreted and do not require dose adjustment for mild-to-moderate chronic kidney disease (CKD). However, gastrointestinal side effects — especially nausea, vomiting, and diarrhea — can cause dehydration that may acutely worsen kidney function in patients with pre-existing CKD. Patients with severe renal impairment (eGFR < 30) should be monitored closely, and some physicians prefer to avoid GLP-1 therapy in this population due to dehydration risk. For liver disease, GLP-1 drugs are metabolized by proteolysis and are not hepatically cleared — no dose adjustment is required, and they may actually benefit patients with metabolic-associated fatty liver disease (MAFLD).
Drug Interactions: Insulin, Sulfonylureas, and Oral Medications
GLP-1 receptor agonists slow gastric emptying, which delays the absorption of any orally administered medication taken at the same time. This is particularly important for narrow-therapeutic-index drugs. Patients on warfarin, levothyroxine, or oral contraceptives should be aware that peak concentrations may shift after starting GLP-1 therapy. When GLP-1 drugs are combined with insulin or sulfonylureas (like glipizide or glimepiride), the risk of hypoglycemia increases significantly — sulfonylurea doses are typically reduced by 50% when initiating GLP-1 therapy. Patients should never adjust their diabetes medications without physician guidance.
Groups Requiring Extra Caution (Not Absolute Contraindications)
Several patient groups are not absolutely contraindicated but require heightened monitoring. Elderly patients (over 75) may be more susceptible to GI side effects and dehydration-related complications. Patients with gastroparesis (delayed gastric emptying) should generally avoid GLP-1 drugs, as the further slowing of gastric emptying can worsen their condition. Patients with a history of diabetic retinopathy treated with insulin who switch to or add GLP-1 therapy have shown transient worsening of retinopathy in some trials (particularly the SUSTAIN-6 trial for semaglutide) — ophthalmologic monitoring is advisable. Patients with active eating disorders or a history of bulimia require psychological evaluation before starting therapy.
The Bottom Line: Always Disclose Your Full History
GLP-1 medications are highly effective for the right patient, but the screening process exists for good reason. Before your appointment, prepare a complete list of your medical history including any endocrine tumors in your family, prior pancreatic disease, kidney function results, current medications (especially diabetes drugs and oral contraceptives), and pregnancy plans. Your physician needs this information to make a safe prescribing decision. If you are prescribed a GLP-1 drug and experience severe abdominal pain, a lump in your neck, difficulty swallowing, or signs of a severe allergic reaction, seek medical care immediately.
Frequently Asked Questions
These answers are for informational purposes only. Always consult your physician for personalized medical advice.
Was this article helpful?
Scientific References & Further Reading
- Wilding JPH et al. — Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021.
- Jastreboff AM et al. — Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022.
- FDA Drug Approvals Database — GLP-1 Receptor Agonists. U.S. Food & Drug Administration.
- PubMed — GLP-1 Receptor Agonist Research Index. National Library of Medicine.
- Mayo Clinic — GLP-1 Agonists for Type 2 Diabetes and Obesity. Mayo Clinic Proceedings.
This content is produced in accordance with GLP-1 Health's editorial standards and is based on peer-reviewed clinical evidence from the sources cited above. It does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication.
